AGN 210676 is a selective prostaglandinEP₂agonist extracted from patent US20070203222A1, Compound example 23, has anEC₅₀of 5 nM.

EC50: 5 nM (EP₂3A receptor), 7749 nM (hDP receptor)^[1]

AGN 210676 (Compound 23) also is a less potent agonist for recombinant human prostaglandin receptors hEP₃A and hDP with EC₅₀s of 153 nM and 7749 nM, respectively. AGN 210676 is useful for the treatment of glaucoma, ocular hypertension, inflammatory bowel disease, and the other diseases or conditions disclosed herein^[1].

431.55

C₂₃H₂₉NO₅S

910562-15-1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.